Replies to post #115714 on Biotech Values

[DewDiligence]

Ipsen’s 1Q11 worldwide Dysport sales were €50.1M, +15% QoQ, +19% YoY (in local currencies):

http://finance.yahoo.com/news/Ipsens-first-quarter-2011-bw-2108649996.html?x=0&.v=1

Dysport, which is sold by MRX for cosmetic indications in the US, continues to be a very distant second to Botox in both medical and cosmetic indications. AGN reports 1Q11 Botox sales tomorrow.